2631 Hanover St
Palo Alto CA 94304

 

New & Events

November 2012.  Oligasis announces fourth and fifth pharmaceutical agreements with Pfizer in which Oligasis will apply its toolkit of Extreme Biopolymers to two additional Pfizer pharmaceutical programs.

April 2012.  Oligasis announces an agreement with a top tier pharmaceutical company in which Oligasis will apply its Extreme Biopolymer platform to one of the Company's pharmaceutical programs.

November 2011.  Oligasis announces third pharmaceutical agreement with Pfizer in which Oligasis will apply its toolkit of Extreme Biopolymers to one of Pfizer's pharmaceutical programs.

November 2011.  Oligasis announces second agreement with a top tier pharmaceutical company in which Oligasis will apply its Extreme Biopolymer platform to one of the Company's pharmaceutical programs.

June 2011.  Oligasis announces second pharmaceutical agreement with Pfizer in which Oligasis will apply its toolkit of Extreme Biopolymers to one of Pfizer's pharmaceutical programs.

June 2011.  Oligasis announces partnership with another top tier pharmaceutical company in which Oligasis will apply its Extreme Biopolymer platform to one of the Company's pharmaceutical programs.

December 2010.  Oligasis announces partnership with a top tier pharmaceutical company in which Oligasis will apply its Extreme Biopolymer platform to one of the Company's pharmaceutical programs.

May 2010.  Oligasis announces pharmaceutical partnership with Pfizer in which Oligasis will apply its toolkit of Extreme Biopolymers to Pfizer's pharmaceutical programs.